We maintain research teams in the following therapeutic focus areas (TFAs):
- Bone Disease
- Cardiovascular Diseases
- Immunity and Inflammation
- Infectious Diseases
- Metabolic Diseases and Obesity
- Muscle Disorders
Each TFA is responsible for target research and validation and pharmacology of product candidates in its therapeutic area. Each TFA has a portfolio of projects underway at any one time. Projects with the greatest scientific and commercial potential advance through preclinical development.
The quality of Regeneron science has been recognized in the academic scientific community as well as through a very tangible metric: our three marketed products as well as every one of our clinical candidates were discovered and validated in Regeneron's labs.
Our Chief Scientific Officer, George D. Yancopoulos, M.D., Ph.D., a member of the National Academy of Sciences, and the President of Regeneron Laboratories, is together with key members of his team a principal inventor and developer of Regeneron's three FDA-approved drugs - including EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection - as well as of its foundation technologies including the TRAP technology, VelociGene®, and VelocImmune®. Our Senior Vice President for Research and Development Sciences, Neil Stahl, Ph.D., was a principal inventor of our Trap technology and before joining Regeneron was a post-doctoral fellow in the laboratory of Nobel Laureate Stanley Prusiner of the University of California at San Francisco. Our Board of Directors includes three Nobelists: Alfred Gilman, M.D., a co-founder of the Company; Michael Brown, M.D.; and Joseph Goldstein, M.D., all Regental Professors at the University of Texas Southwestern Medical Center at Dallas.
The business leadership at Regeneron is also steeped in science and medicine: Len Schleifer, our President and CEO, is a board-certified neurologist and Ph.D. in Pharmacology. Roy Vagelos, our Chairman, is a physician and former head of research and development, and a former CEO, of Merck.
Kevin Bailey, VP
Pre-clinical Manufacturing and Process Development
Tom Daly, VP
Clinical Development and Protein Chemistry
Jim Fandl, SVP
Protein Expression Sciences
Neil Graham, VP
Drew Murphy, SVP
Research, Regeneron Laboratories
Bill Olson, VP
Research and Development, Therapeutic Proteins
Nick Papadopoulos, SVP
Bill Sasiela, VP
Randy Soltys, VP
Drug Safety and Pharmacometrics
Gavin Thurston, VP
Oncology and Angiogenesis
Pam Trail, VP
David Valenzuela, VP
Functional Genomics and Chief of VelociGene Operations